Your session is about to expire
← Back to Search
Cancer Vaccine
RNA-Nanoparticle Vaccine for Melanoma Recurrence
Phase 1
Recruiting
Led By Bently Doonan, MD, MS
Research Sponsored by University of Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Subjects must not have more than one active malignancy at the time of enrollment
ECOG performance ≤ 1
Must not have
Subjects with unstable angina pectoris
Females or males of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 4 months after the last dose of study treatment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial will assess if a vaccine can safely stop melanoma progression in those who have not responded to anti-PD1 therapy.
Who is the study for?
This trial is for adults over 18 with stage IIB-IV melanoma that worsened on anti-PD1 therapy. They must be in good physical condition, not have multiple cancers, and agree to use birth control. The disease must allow for vaccine creation from a surgical sample, and they can't have had certain treatments or conditions that would risk their safety.
What is being tested?
The study tests a new RNA-nanoparticle (RNA-NP) vaccine made from the patient's own tumor material against early melanoma recurrence after previous anti-PD-1 antibody treatment. It aims to see if this personalized vaccine is safe and feasible as a treatment option.
What are the potential side effects?
Potential side effects are not detailed but may include typical reactions to vaccines such as soreness at the injection site, fever, fatigue, or allergic reactions due to components of the vaccine or its method of delivery.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I do not have more than one active cancer.
Select...
I am fully active and can carry on all my pre-disease activities without restriction.
Select...
I am a woman who can have children and have a negative pregnancy test.
Select...
My cancer does not have the BRAF mutation.
Select...
I received PD1 or PD1/CTLA-4 inhibitors for melanoma after surgery.
Select...
My liver and kidney functions are within the required ranges.
Select...
My condition can be sampled through surgery for vaccine development.
Select...
My melanoma worsened during or soon after adjuvant immunotherapy.
Select...
I am 18 years old or older.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have unstable chest pain.
Select...
I am willing and able to use birth control during and for 4 months after the study.
Select...
I am currently pregnant or breastfeeding.
Select...
I have had my spleen removed.
Select...
I haven't needed IV drugs for an infection within a week before my vaccine creation or administration.
Select...
I have active hepatitis B or untreated hepatitis C.
Select...
I have an active autoimmune disease that affects my daily life.
Select...
I have severe symptoms from heart failure.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Feasibility of treatment with RNA-NP vaccine
Maximum tolerated dose
Secondary study objectives
Overall response rate
Progression-free survival
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: mRNA-nanoparticle (mRNA-NP) vaccineExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
University of FloridaLead Sponsor
1,409 Previous Clinical Trials
767,535 Total Patients Enrolled
4 Trials studying Melanoma
126 Patients Enrolled for Melanoma
Bently Doonan, MD, MSPrincipal InvestigatorUniversity of Florida
2 Previous Clinical Trials
61 Total Patients Enrolled
1 Trials studying Melanoma
29 Patients Enrolled for Melanoma